Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sunitinib with regorafenib falls short for metastatic GIST

Serrano C et al. ASCO 2018 Abstract 11510.

Key clinical point: The strategy of rapid alteration of drugs to overcome imatinib resistance mutation in gastrointestinal stromal tumor (GIST) is feasible but was ineffective.

Major finding: There were no objective responses among 12 patients treated continuously with 3 days of sunitinib (Sutent) followed by 4 days of regorafenib (Stivarga). Although four patients had stable disease in the short term, in each case the disease progressed within 16 weeks.

Study details: Phase Ib clinical trial in 12 patients with heavily pre-treated metastatic GIST.

Disclosures: The study was supported by an ASCO Young Investigator Award, Pfizer, and Bayer. Dr. Serrano disclosed honoraria from Bayer, a consulting or advisory role for Deciphera, research funding from Bayer and Deciphera, and travel accommodations and expenses from Pfizer.

Source: Serrano C et al. ASCO 2018 Abstract 11510.


Serrano C et al. ASCO 2018 Abstract 11510.